Followers | 813 |
Posts | 71327 |
Boards Moderated | 2 |
Alias Born | 01/30/2003 |
Tuesday, November 17, 2015 6:11:14 PM
In other news, major shareholder Vivo Ventures Vii, Llc sold 390,572 shares of MEI Pharma stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $1.84, for a total value of $718,652.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
MEIP has been the topic of several research reports. Wedbush restated a “hold” rating on shares of MEI Pharma in a research report on Friday, September 4th. Cowen and Company reiterated a “buy” rating on shares of MEI Pharma in a research report on Wednesday, October 7th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of MEI Pharma in a report on Wednesday, September 2nd.
MEI Pharma (NASDAQ:MEIP) traded down 0.7349% during midday trading on Tuesday, hitting $1.6478. 233,965 shares of the stock traded hands. The company’s market cap is $56.28 million. The firm’s 50-day moving average is $1.73 and its 200-day moving average is $1.78. MEI Pharma has a 52-week low of $1.47 and a 52-week high of $7.14.
MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Analysts predict that MEI Pharma will post ($0.67) EPS for the current year.
MEI Pharma, Inc. is an oncology business. The Firm is concentrated on the clinical development of drugs and treatments for treatment of cancer. The business ‘s portfolio of clinical drug candidates includes Pracinostat, ME- PWT143 and 344. Pracinostat is an orally available histone deacetylase (NASDAQ:MEIP) inhibitor indicated for the treatment of hematologic disorders that are advanced, like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-established mitochondrial inhibitor targeting a mitochondrial element of the terminal respiratory chain complex. PWT143 is an oral inhibitor -kinase (PI3K) delta, a molecular target that plays an essential role in the proliferation and survival of hematologic cancer cells. Pracinostat continues to be examined in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
http://midsouthnewz.com/mei-pharma-receives-2-25-average-price-target-from-analysts-nasdaqmeip/20829/
Recent MEIP News
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
- MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 • Business Wire • 01/16/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 10:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:26:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:25:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 • Business Wire • 12/11/2023 05:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 01:59:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:06:11 PM
- MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM